Reata Selected to Present Early-Stage Programs at the BIO Asia International Conference
March 16 2018 - 4:15PM
Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (Reata or Company),
a clinical-stage biopharmaceutical company, today announced that
Chief Development Officer, Keith Ward, Ph.D., will present at the
15th Annual BIO Asia International Conference on Tuesday, March 20,
2018, at 8:30 a.m. JST in Tokyo, Japan. The BIO Asia
conference is a premier partnering-focused event for the
biopharmaceutical industry, and Reata’s selection as a presenting
company highlights the strength of its early-stage assets,
including RTA 901 and RTA 1701.
RTA 901 is a highly potent and selective
C-terminal inhibitor of Hsp90, which has a critical role in
mitochondrial function, protein folding, and inflammation.
RTA 901 demonstrates profound efficacy in a wide range of animal
models of neurologic disease, including diabetic neuropathy and
demyelinating nerve injury. RTA 901 has been evaluated in a
Phase 1 clinical trial in healthy volunteers, with no safety or
tolerability issues and with an acceptable pharmacokinetic
profile.
RTA 1701 is a novel, small-molecule, orally
bioavailable RORγt inhibitor that is currently in preclinical
testing. RORγt is the master regulator of human T Helper 17
(Th17), cellular differentiation, function, and cytokine
production, and is a compelling target for a variety of autoimmune
and inflammatory conditions.
About Reata Pharmaceuticals,
Inc.
Reata is a clinical-stage biopharmaceutical
company that develops novel therapeutics for patients with serious
or life-threatening diseases by targeting molecular pathways
involved in the regulation of cellular metabolism and inflammation.
Reata’s two most advanced clinical candidates, bardoxolone methyl
and omaveloxolone, target the important transcription factor Nrf2
that promotes the resolution of inflammation by restoring
mitochondrial function, reducing oxidative stress, and inhibiting
pro-inflammatory signaling.
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements,” including, without
limitation, statements regarding the success, cost and timing of
our product development activities and clinical trials, our plans
to research, develop and commercialize our product candidates, and
our ability to obtain and retain regulatory approval of our product
candidates. You can identify forward-looking statements
because they contain words such as “believes,” “will,” “may,”
“aims,” “plans,” and “expects.” Forward-looking statements
are based on Reata’s current expectations and assumptions.
Because forward-looking statements relate to the future, they are
subject to inherent uncertainties, risks, and changes in
circumstances that may differ materially from those contemplated by
the forward-looking statements, which are neither statements of
historical fact nor guarantees or assurances of future
performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements include, but are not limited to, (i) the timing, costs,
conduct, and outcome of our clinical trials and future preclinical
studies and clinical trials, including the timing of the initiation
and availability of data from such trials; (ii) the timing and
likelihood of regulatory filings and approvals for our product
candidates; (iii) the potential market size and the size of the
patient populations for our product candidates, if approved for
commercial use, and the market opportunities for our product
candidates; and (iv) other factors set forth in Reata’s filings
with the U.S. Securities and Exchange Commission, including its
Annual Report on Form 10-K, under the caption “Risk Factors.”
The forward-looking statements speak only as of the date made and,
other than as required by law, we undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.
Contact: Reata Pharmaceuticals, Inc.(972)
865-2219info@reatapharma.comhttp://news.reatapharma.com
Investor Relations:Vinny JindalVice President,
Strategy(469) 374-8721ir@reatapharma.com
Media:Matt Middleman, M.D.LifeSci Public
Relations(646)
627-8384matt.middleman@lifescipublicrelations.com
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Sep 2023 to Sep 2024